Veru INC. (VERU) — 10-K Filings
All 10-K filings from Veru INC.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Veru Shifts Focus to Cardiometabolic Drugs, Divests FC2 Business
— Dec 17, 2025 Risk: high
VERU INC. (VERU) is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases, as deta -
Veru Inc. Reports FY24 Results: $148.6M Assets, $93.9M Net Loss
— Dec 16, 2024 Risk: medium
Veru Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting total assets of $148.6 million and total liabilities of $2.2 million. The comp
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX